Pfizer
Search results
1 day ago · Clesrovimab met all primary safety and efficacy endpoints Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from its Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab (MK-1654), the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease ...
1 day ago · Merck's antibody-based shot met the main goal of a mid-to-late stage trial, when tested to protect infants against a disease caused by the respiratory syncytial virus (RSV), the company said on ...
1 day ago · Clesrovimab met all primary safety and efficacy endpoints RAHWAY, N.J., July 23, 2024 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) (NYSE: MRK) today announced positive topline results from its Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab (MK-1654), the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory ...
1 day ago · Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Gene Therapy Research Institution Co., Ltd. (GTRI), a Japanese clinical-stage biotech start-up specializing in gene therapy using adeno-associated virus (AAV) vectors. GTRI will utilize Merck’s Sf-RVN ® Insect Cell Line platform ...
1 day ago · Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men ...
2 days ago · On Tuesday, Merck & Co Inc MRK shared topline results from its Phase 2b/3 clinical trial (MK-1654-004) of clesrovimab (MK-1654). Clesrovimab is the company’s investigational prophylactic ...
2 days ago · Merck & Co. led the antibody-drug conjugate (ADC) shopping spree last year with its multi-billion dollar deal with Daiichi Sankyo, but now the U.S. pharma clearly wants to further fine-tune its ADC pipeline. To this end, Merck has signed a small deal worth up to $208 million, which includes milestone payments, to acquire a University…
